![[dr. bob]](/dr-bob-sm.gif)
Dr. Bob is Robert Hsiung, MD,
bob@dr-bob.orgShown: posts 1 to 10 of 10. This is the beginning of the thread.
Posted by BobS. on February 9, 2011, at 12:36:52
Does anyone have any thoughts on this new drug or preferably used it in a clinical trial?
Thank you BobS.
Posted by Phillipa on February 9, 2011, at 13:37:50
In reply to Latuda - Opinions, posted by BobS. on February 9, 2011, at 12:36:52
Latuda is that the valdozine sp? Phillipa
Posted by Phillipa on February 9, 2011, at 13:39:47
In reply to Re: Latuda - Opinions » BobS., posted by Phillipa on February 9, 2011, at 13:37:50
Sorry googled it for scizophrenic sounds like same side effects to me. Phillipa
Posted by bodhisattva_guy on February 10, 2011, at 0:04:12
In reply to Re: Latuda - Opinions, posted by Phillipa on February 9, 2011, at 13:39:47
Oh you two! Respecfully, without confrontation, I'll just add the info which might be relevant to some:
"Lurasidone has a unique receptor-binding capability with high affinity for dopamine-2, serotonin-2A, serotonin-7, serotonin-1A and noradrenaline-2c receptors. These receptors are known to improve cognitive capabilities upon effective regulation. The drug has limited affinity for histamine-1 and acetylcholine-M1 receptors. Lurasidone is also a partial agonist for the serotonin 5HT1A receptor. It enhances the functions of muscarinic acetylcholine receptors, which are known to aid in memory and learning functions.
-----
In clinical trials, Lurasidone has shown its efficacy in treating both positive and negative symptoms of schizophrenia. Significant improvements in the cognitive symptoms have also been noticed with the use of the drug. The safety profile of the drug is also good with minimal weight gain and metabolic effects. As a result, use of Lurasidone may not necessitate co-administration of anti-cholinergics, which are known to impair cognition.Lurasidone clinical trials
The development of Lurasidone involved more than 40 clinical trials. Phase II trials included two six-week randomised double-blind placebo-controlled studies carried out across the US. The studies indicated that Lurasidone was well tolerated in patients and showed greater efficacy compared to the placebo group.
Phase III studies of Lurasidone included two Program to Evaluate the Antipsychotic Response to Lurasidone (PEARL) trials conducted across the world. PEARL 1 was a six-week placebo-controlled double-blind, trial which started in October 2007. The study recruited 500 patients in 51 centres across the US, Europe and Asia. The majority of the patients recruited were male with an average age of 39 years.
In May 2009, DSP announced positive results from PEARL 1 study. The results indicated that Lurasidone was more effective in treating acute schizophrenia compared with the placebo."
- http://www.drugdevelopment-technology.com/projects/lurasidone/I wonder why will we see trials of efficacy of this new drug versus older atypicals?
Perhaps there is one, I have browsed pubmed yet
Posted by Zyprexa on February 10, 2011, at 4:45:50
In reply to Latuda - Opinions, posted by BobS. on February 9, 2011, at 12:36:52
I've read the perscribing info on it. It seems to be sedating and have a high incidence of EPS simptoms. It also has a shortish half life of 18 hours, so you would probably have to take it twice a day. Also it has to be taken with a sizeable amount of food. One good thing is its weight nutrule.
I'm probably not going to take it since I'm having good results from zyprexa and perphenazine. Don't want to possibly get my head out of wack again with med trials, when I have some thing good.
Posted by bodhisattva_guy on February 10, 2011, at 21:29:44
In reply to Re: Latuda - Opinions, posted by Zyprexa on February 10, 2011, at 4:45:50
18 hours is definitely not shortish - in 36 hours (a day and a half) you still have 1/2 of original dose. This makes no need to take it twice. Do not talk non sense without explaining it.
Posted by bodhisattva_guy on February 10, 2011, at 21:38:16
In reply to Re: Latuda - Opinions, posted by bodhisattva_guy on February 10, 2011, at 21:29:44
On that note, I shall explain myself:
Studies have shown that 80 mg (40-120 mg) is effective, rapid onset of symptom reduction. It appears to lack QTc prolongation. Once a day administration is possible with low extraparymidal, weights gain, akathisia side effects.
Posted by Zyprexa on February 11, 2011, at 3:14:16
In reply to Re: Latuda - Opinions, posted by bodhisattva_guy on February 10, 2011, at 21:29:44
Half life of 18 hours means you only have half left after 18 hours. I guess you might get away with once daily, but if it were me I would probably split the dose. I honestly don't know how its prescribed, but this is my interpretation.
Posted by Conundrum on February 11, 2011, at 11:48:06
In reply to Re: Latuda - Opinions, posted by bodhisattva_guy on February 10, 2011, at 21:29:44
> 18 hours is definitely not shortish - in 36 hours (a day and a half) you still have 1/2 of original dose. This makes no need to take it twice. Do not talk non sense without explaining it.
???
18 hour half life is straight forward. After 18 hours you have half the original dose. That would probably require twice daily dosing.
Posted by Phillipa on February 11, 2011, at 18:56:23
In reply to Re: Latuda - Opinions » bodhisattva_guy, posted by Conundrum on February 11, 2011, at 11:48:06
Agree with zyprexa and Conundum. Twice a day. Phillipa
This is the end of the thread.
Psycho-Babble Medication | Extras | FAQ
Dr. Bob is Robert Hsiung, MD,
bob@dr-bob.org
Script revised: February 4, 2008
URL: http://www.dr-bob.org/cgi-bin/pb/mget.pl
Copyright 2006-17 Robert Hsiung.
Owned and operated by Dr. Bob LLC and not the University of Chicago.